BioCryst Pharmaceuticals Inc (BCRX) stock
BCRXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$7.61−0.07 (-0.91%)
Close on Nov 13, 2026Market cap $1.94BP/E –Yield –
BioCryst Pharmaceuticals statistics
88 measures from SEC filings and the closing price. Hover a name for the formula; the last column is the median of companies in the same industry group.
Important dates
- Next earnings
- Feb 25, 2027 (estimated, before the open)
- Last ex-dividend date
- No dividends
- Fundamentals through
- Sep 30, 2026
- Share price as of
- Nov 13, 2026
Valuation ratiosIndustry
- P/OCF Ratio
- 5.29
- 12.99
Enterprise valuationIndustry
- EV / Sales
- 2.04
- 2.57
- EV / FCF
- 5.37
- 22.27
Share statisticsIndustry
- Shares Change (YoY)
- 15.3%
- 10.8%
- Shares Change (QoQ)
- 0.33%
- 0.50%
- Float
- 251M
- 49M
- Shares Held by Insiders
- 1.91%
- 11.7%
- Shares Held by Institutions
- 103.3%
- 56.4%
Short sellingIndustry
- Short Interest
- 28M
- –
- Short Interest Change
- 3.91%
- -0.80%
- Short % of Float
- 11.0%
- 9.01%
- Short % of Shares Outstanding
- 10.8%
- 6.30%
- Days to Cover
- 5.09
- 5.15
Stock price statisticsIndustry
- 52-Week High
- $11.22
- –
- 52-Week Low
- $6.23
- –
- 20-Day Moving Average
- $7.95
- –
- 50-Day Moving Average
- $8.23
- –
- 200-Day Moving Average
- $8.80
- –
- Average True Range (14)
- $0.35
- –
- Price Change (1 Week)
- -1.04%
- -1.15%
- Price Change (1 Month)
- -5.11%
- -4.87%
- Price Change (3 Months)
- -23.4%
- -21.0%
- Price Change (6 Months)
- -15.6%
- -20.6%
- Price Change (YTD)
- -2.44%
- -23.6%
- Price Change (1 Year)
- 5.99%
- -22.4%
- Price Change (3 Years)
- 43.0%
- -29.5%
- Price Change (5 Years)
- -37.9%
- -77.9%
- Price Change (10 Years)
- 34.0%
- -65.4%
- Average Volume (10 Days)
- 6M
- –
- Average Volume (20 Days)
- 6M
- –
- Average Volume (90 Days)
- 4M
- –
- Relative Volume
- 0.51
- 0.70
- Relative Strength Index (14)
- 40.7
- 43.4
- Volatility (1 Year)
- 48.1%
- 80.1%
- Beta (5 Years)
- 0.79
- 1.07
MarginsIndustry
- Pretax Margin
- -36.9%
- -11.6%
- EBITDA Margin
- -30.1%
- -27.7%
- FCF Margin
- 38.0%
- -9.56%
Returns on capitalIndustry
- Return on Assets (ROA)
- -69.3%
- -40.6%
- Return on Capital Employed (ROCE)
- -73.2%
- -37.9%
Financial positionIndustry
- Current Ratio
- 2.71
- 3.30
- Quick Ratio
- 2.54
- 2.39
- Debt / FCF
- 1.08
- 4.65
- Interest Coverage
- -3.77
- -6.35
GrowthIndustry
- Revenue Growth (YoY)
- 60.3%
- 6.82%
- FCF Growth (YoY)
- 664.5%
- 6.85%
- Revenue Growth (3Y CAGR)
- 47.8%
- 2.25%
- Revenue Growth (5Y CAGR)
- 117.9%
- 6.41%
EfficiencyIndustry
- Asset Turnover
- 1.85
- 0.40
- Inventory Turnover
- 2.14
- 2.73
- Revenue Per Employee
- $2.21M
- $429.29K
- Profits Per Employee
- -$826.80K
- -$689.41K
- Employee Count
- 435
- 74
- WACC
- 9.55%
- 10.2%
Income statement (TTM)Industry
- Pretax Income
- -$354.73M
- -$12.95M
Balance sheetIndustry
- Net Cash (Debt)
- -$20.61M
- $17.76M
- Net Cash Per Share
- -$0.08
- $0.80
- Equity (Book Value)
- -$397.38M
- $53.89M
- Book Value Per Share
- -$1.56
- $1.50
- Tangible Book Value
- -$397.38M
- $27.13M
- Working Capital
- $335.32M
- $79.99M
Cash flow (TTM)Industry
- Capital Expenditures
- -$1.65M
- -$1.00M
- FCF Per Share
- $1.43
- -$0.42
Dividends and yieldsIndustry
- Earnings Yield
- -18.5%
- -21.8%
- FCF Yield
- 18.8%
- -9.44%
Taxes and interestIndustry
- Interest Expense
- $76.81M
- $2.90M
- Income Tax
- $4.92M
- $73.00K
Scores and fair valueIndustry
- Altman Z-Score
- -3.13
- 0.23
- Piotroski F-Score
- 7
- 4
- Beneish M-Score
- -2.19
- -2.63
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.
| Period | BCRX | S&P 500 | Difference | BCRX per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -5.7% | -3.0% | −2.7 pts | ||
| 3 months | -22.4% | -2.8% | −19.6 pts | ||
| Year to date | -2.4% | +11.5% | −13.9 pts | ||
| 1 year | +10.3% | +13.5% | −3.2 pts | ||
| 3 years | +47.8% | +77.7% | −29.9 pts | +13.9% | +21.1% |
| 5 years | -37.9% | +72.6% | −110.5 pts | -9.1% | +11.5% |
| 10 years | +42.5% | +308.2% | −265.7 pts | +3.6% | +15.1% |
Short interest
Shares sold short and not yet covered, reported by brokers to FINRA twice a month. Latest settlement date Oct 30, 2026.
28M BCRX shares were sold short on Oct 30, 2026, up 3.9% from the previous report, or 11.03% of the shares available to trade. At recent volumes it would take 5.1 days to buy them back. Over the last 20 sessions, 38.5% of the volume reported to FINRA was short selling.
| Settlement date | Shares short | Change | Avg. daily volume | Days to cover |
|---|---|---|---|---|
| Oct 30, 2026 | 27,637,852 | +3.9% | 5,429,684 | 5.1 |
| Oct 15, 2026 | 26,597,263 | -3.3% | 4,579,954 | 5.8 |
| Sep 30, 2026 | 27,494,721 | -21.1% | 5,955,260 | 4.6 |
| Sep 15, 2026 | 34,868,460 | +2.4% | 4,780,741 | 7.3 |
| Aug 31, 2026 | 34,050,906 | +3.4% | 2,358,431 | 14.4 |
| Aug 14, 2026 | 32,939,174 | +0.4% | 4,132,288 | 8.0 |
| Jul 31, 2026 | 32,804,839 | +5.1% | 2,638,326 | 12.4 |
| Jul 15, 2026 | 31,208,457 | -35.9% | 5,245,936 | 6.0 |
| Jun 30, 2026 | 48,685,241 | +19.8% | 8,122,433 | 6.0 |
| Jun 15, 2026 | 40,642,061 | +10.9% | 3,566,719 | 11.4 |
| May 29, 2026 | 36,651,044 | +1.5% | 3,916,568 | 9.4 |
| May 15, 2026 | 36,106,472 | -3.5% | 5,931,038 | 6.1 |
Ratios use trailing-twelve-month results and the latest balance sheet. How we calculate.
See a number that looks wrong?